Bayer Links OTC User Fees To Exclusivity, Hisamitsu Pans General Concept
Bayer HealthCare encourages FDA to grant periods of market exclusivity to firms charged user fees for monograph proposal, while Hisamitsu America questions FDA's basic rationale for why a fee is needed to improve the monograph system.
You may also be interested in...
Sensodyne shines for Glaxo-Novartis JV; and international growth leads Prestige Brands OTCs.
While Director Janet Woodcock and other CDER officials explain the center's reasons for proposing a monograph program user fee, some stakeholders suggest the agency explain more about how the program would work.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.